According to prior research, PTEN inactivation might have greater clinical relevance in contributing to primary resistance in colorectal cancer treatment, given a rare co-occurrence of PTEN inactivation or PIK3CA activating mutations with KRAS mutations in lung cancer, in contrast to their 42.4% co-occurrence rate in colorectal cancer.119. The gene discussed is KRAS; the disease is lung carcinoma.